Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · IEX Real-Time Price · USD
7.59
+0.31 (4.26%)
May 2, 2024, 4:00 PM EDT - Market closed
Tango Therapeutics Employees
Tango Therapeutics had 140 employees on December 31, 2023. The number of employees increased by 30 or 27.27% compared to the previous year.
Employees
140
Change (1Y)
30
Growth (1Y)
27.27%
Revenue / Employee
$260,907
Profits / Employee
-$726,743
Market Cap
809.99M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 140 | 30 | 27.27% |
Dec 31, 2022 | 110 | 19 | 20.88% |
Dec 31, 2021 | 91 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
TNGX News
- 4 weeks ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights - Business Wire
- 2 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference - GlobeNewsWire
- 4 months ago - Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study - PRNewsWire
- 6 months ago - Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting - GlobeNewsWire
- 6 months ago - Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights - GlobeNewsWire